11,227 results match your criteria Lymphoma Follicular


Germinal center-derived lymphomas: The darkest side of humoral immunity.

Immunol Rev 2019 Mar;288(1):214-239

Department of Medicine, Division of Hematology & Medical Oncology, Weill Cornell Medicine, New York City, New York.

One of the unusual features of germinal center (GC) B cells is that they manifest many hallmarks of cancer cells. Accordingly, most B-cell neoplasms originate from the GC reaction, and characteristically display abundant point mutations, structural genomic lesions, and clonal diversity from the genetic and epigenetic standpoints. The dominant biological theme of GC-derived lymphomas is mutation of genes involved in epigenetic regulation and immune receptor signaling, which come into play at critical transitional stages of the GC reaction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/imr.12755DOI Listing

Molecular pathogenesis of germinal center-derived B cell lymphomas.

Immunol Rev 2019 Mar;288(1):240-261

Pathology and Cell Biology, Institute for Cancer Genetics, Columbia University, New York City, New York.

B cell lymphomas comprise a heterogeneous group of genetically, biologically, and clinically distinct neoplasms that, in most cases, originate from the clonal expansion of B cells in the germinal center (GC). In recent years, the advent of novel genomics technologies has revolutionized our understanding of the molecular pathogenesis of lymphoid malignancies as a multistep process that requires the progressive accumulation of multiple genetic and epigenetic alterations. A common theme that emerged from these studies is the ability of lymphoma cells to co-opt the same biological programs and signal transduction networks that operate during the normal GC reaction, and misuse them for their own survival advantage. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/imr.12745DOI Listing

MYC in Germinal Center-derived lymphomas: Mechanisms and therapeutic opportunities.

Immunol Rev 2019 Mar;288(1):178-197

Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.

The rearrangement of immunoglobulin loci during the germinal center reaction is associated with an increased risk of chromosomal translocations that activate oncogenes such as MYC, BCL2 or BCL6, thus contributing to the development of B-cell lymphomas. MYC and BCL2 activation are initiating events in Burkitt's (BL) and Follicular Lymphoma (FL), respectively, but can occur at later stages in other subtypes such as Diffuse Large-B Cell Lymphoma (DLBCL). MYC can also be activated during the progression of FL to the transformed stage. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/imr.12734DOI Listing

Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab.

J Immunother Cancer 2019 Mar 12;7(1):70. Epub 2019 Mar 12.

Department of Human Oncology, University of Wisconsin, Madison, WI, USA.

Background: The ECOG-ACRIN Cancer Research Group evaluated rituximab treatment schedules for patients with newly-diagnosed low-tumor-burden follicular-lymphoma (FL). All patients received 4-weekly rituximab treatments as induction therapy. Clinically-responding patients were randomized to receive rituximab every 13 weeks ("maintenance") vs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0538-8DOI Listing
March 2019
1 Read

Significance of PD-L1 in the diagnosis and treatment of B-cell malignant lymphoma.

Oncol Lett 2019 Mar 28;17(3):3382-3386. Epub 2019 Jan 28.

Department of Cardiothoracic Surgery, Suizhou Central Hospital, Suizhou, Hubei 441300, P.R. China.

The present study explored the significance of programmed death-ligand 1 (PD-L1) molecules in the diagnosis and treatment of B-cell malignant lymphoma. A total of 92 patients with B-cell malignant lymphoma (experimental group), admitted to the Quanzhou First Hospital Affiliated to Fujian Medical University from February 2014 to May 2017, and 60 healthy subjects (control group) were enrolled in this study and their clinical data were retrospectively analyzed. Plasma levels of PD-L1 before treatment and at 5, 10, and 15 days after treatment were measured by ELISA. Read More

View Article

Download full-text PDF

Source
http://www.spandidos-publications.com/10.3892/ol.2019.9982
Publisher Site
http://dx.doi.org/10.3892/ol.2019.9982DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396271PMC
March 2019
1 Read

Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first line immunochemotherapy.

Br J Clin Pharmacol 2019 Mar 13. Epub 2019 Mar 13.

Pharma Development Oncology, F. Hoffmann-La Roche, Basel, Switzerland.

Aims: Obinutuzumab (G) is a humanized type II, Fc-glycoengineered anti-CD20 monoclonal antibody used in various indications, including patients with previously untreated follicular lymphoma (1L FL). We investigated sources of variability in G exposure and association of progression-free survival (PFS) with average concentration over induction (C ) in 1L FL patients treated with G plus chemotherapy (bendamustine, CHOP, or CVP) in the GALLIUM trial.

Methods: Individual exposures (C ) were obtained from a previously established population pharmacokinetic model updated with GALLIUM data. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bcp.13920DOI Listing

Transcriptional factor ATF3 protects against colitis by regulating follicular helper T cells in Peyer's patches.

Proc Natl Acad Sci U S A 2019 Mar 12. Epub 2019 Mar 12.

Joint Program in Immunology, Department of Internal Medicine, Affiliated Guangzhou Women and Children's Medical Center, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510623, China;

Disruption of mucosal immunity plays a critical role in the pathogenesis of inflammatory bowel disease, yet its mechanism remains not fully elucidated. Here, we found that activating transcription factor 3 (ATF3) protects against colitis by regulating follicular helper T (T) cells in the gut. The expression of ATF3 in CD4 T cells was negatively correlated with the severity of ulcerative colitis in clinical patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1818164116DOI Listing

Florid T-follicular helper cell hyperplasia associated with extranodal marginal zone lymphoma: a diagnostic pitfall which may mimic T cell lymphoma.

Histopathology 2019 Mar 12. Epub 2019 Mar 12.

Department of Cellular Pathology, The Royal Marsden Hospital, London, SW3 6JJ.

A 62-year old female with a history of myasthenia gravis presented in January 2016 with worsening diplopia. There was a left orbital mass with initial biopsy showing fibrosis and minimal chronic inflammation, insufficient for a diagnosis of lymphoma. Anaemia was detected on routine blood tests in November 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/his.13858DOI Listing
March 2019
1 Read

Follicular lymphoma suggested to transform into EBV-negative plasmablastic lymphoma.

Int J Hematol 2019 Mar 11. Epub 2019 Mar 11.

First Department of Internal Medicine, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan.

Follicular lymphoma (FL) is an indolent lymphoma that often transforms into a high-grade lymphoma, mostly diffuse large B-cell lymphoma. A case of FL suggested to transform into plasmablastic lymphoma is presented. A 59-year-old man was admitted to our hospital because of right lower abdominal pain and vomiting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-019-02591-4DOI Listing

Salvage treatment and survival for relapsed follicular lymphoma following primary radiotherapy: A collaborative study on behalf of ILROG.

Int J Radiat Oncol Biol Phys 2019 Mar 8. Epub 2019 Mar 8.

Stanford Cancer Institute and Stanford University School of Medicine.

Purpose/objective(s): We previously reported ∼30% of patients with localized follicular lymphoma (FL) staged by F-FDG-PET-CT (PET-CT) receiving primary radiotherapy (RT) will relapse within 5 years. We sought to report outcomes for those who relapsed.

Materials/methods: We conducted a multicenter retrospective study of patients who received RT≥24Gy for stage I-II FL grade 1-3A FL, with age≥18 years, and PET-CT staging. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03603016193031
Publisher Site
http://dx.doi.org/10.1016/j.ijrobp.2019.03.004DOI Listing
March 2019
1 Read

Economic burden and treatment patterns for patients with diffuse large B-cell lymphoma and follicular lymphoma in the USA.

J Comp Eff Res 2019 Mar 11. Epub 2019 Mar 11.

Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.

Aim: Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) are common types of non-Hodgkin's lymphoma, and real-world evidence continues to be lacking for healthcare costs and utilization among DLBCL and FL patients. Our study aims to describe medical and pharmacy costs and health resource utilization and to characterize longitudinal treatment patterns among these patients.

Methods: A retrospective observational study was performed among adult patients with DLBCL or FL using the US MarketScan (Truven) administrative claims data from 1 January 2007 to 31 December 2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/cer-2018-0094DOI Listing

Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial.

Blood 2019 Mar 8. Epub 2019 Mar 8.

Univ. Lille, CHU Lille, EA 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associees, Lille, France.

Novel strategies, such as chemosensitization with targeted agents, that build on the success of standard immunochemotherapy show promise for the treatment of non-Hodgkin lymphoma (NHL). Here, we report a phase 1b study investigating dose escalation of the BCL2 inhibitor, venetoclax, in combination with rituximab or obinutuzumab and cyclophosphamide, doxorubicin, vincristine, and prednisone (R-/G-CHOP) chemotherapy in B-cell NHL. Objectives included safety assessment and determination of a recommended phase 2 dose (RP2D). Read More

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/lookup/doi/10.1182/blood-2018-11
Publisher Site
http://dx.doi.org/10.1182/blood-2018-11-880526DOI Listing
March 2019
9 Reads

The impact of rheumatological disorders on lymphomas and myeloma: a report on risk and survival from the UK's population-based Haematological Malignancy Research Network.

Cancer Epidemiol 2019 Mar 4;59:236-243. Epub 2019 Mar 4.

Department of Health Sciences, University of York, York, UK.

Background: Autoimmune inflammatory disease increases the risk of diffuse large B-cell lymphoma (DLBCL) and marginal zone lymphoma (MZL), but findings for other mature B-cell malignancies are equivocal. Furthermore, it has been suggested that the increase in DLBCL is due to the activated B-cell (ABC) subtype; but data on this, and the impact of inflammatory co-morbidities on survival, are sparse and contradictory.

Methods: Data are from an established UK population-based cohort. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canep.2019.02.014DOI Listing
March 2019
2 Reads

Impact of B cell/lymphoid stromal cell crosstalk in B-cell physiology and malignancy.

Immunol Lett 2019 Mar 4. Epub 2019 Mar 4.

UMR_S 1236, Université Rennes 1, INSERM, Etablissement Français du Sang, F-35000, Rennes, France; SITI, Pôle de Biologie, CHU Pontchaillou, F-35000, Rennes, France. Electronic address:

Stromal cells have been considered for a long time essentially as a structural component organizing tissue architecture, including those of secondary lymphoid organs. More recently, highly specialized stromal cell subsets were shown to differentially organize immune cell recruitment, survival, and differentiation within lymph nodes. In particular, mature B cells interact with different lymphoid stromal cell networks through bidirectional interactions involving cell-cell contact and soluble factors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.imlet.2019.02.005DOI Listing
March 2019
1 Read

S-Geranylgeranyl-L-glutathione is a ligand for human B cell-confinement receptor P2RY8.

Nature 2019 Mar 6;567(7747):244-248. Epub 2019 Mar 6.

Howard Hughes Medical Institute and Department of Microbiology and Immunology, University of California, San Francisco, CA, USA.

Germinal centres are important sites for antibody diversification and affinity maturation, and are also a common origin of B cell malignancies. Despite being made up of motile cells, germinal centres are tightly confined within B cell follicles. The cues that promote this confinement are incompletely understood. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41586-019-1003-zDOI Listing
March 2019
4 Reads

The histone methyltransferase EZH2 primes the early differentiation of follicular helper T cells during acute viral infection.

Cell Mol Immunol 2019 Mar 6. Epub 2019 Mar 6.

Institute of Immunology, PLA, Third Military Medical University, 400038, Chongqing, China.

Epigenetic modifications to histones dictate the differentiation of naïve CD4 T cells into different subsets of effector T helper (T) cells. The histone methyltransferase enhancer of zeste homolog 2 (EZH2) has been implicated in the mechanism regulating the differentiation of T1, T2 and regulatory T (T) cells. However, whether and how EZH2 regulates follicular helper T (T) cell differentiation remain unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41423-019-0219-zDOI Listing
March 2019
2 Reads
4.112 Impact Factor

Transformed Follicular Lymphoma in the Rituximab Era: A Report from the Spanish Lymphoma Oncology Group.

Hematol Oncol 2019 Mar 6. Epub 2019 Mar 6.

Medical Oncology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain.

Follicular lymphoma (FL) is the second most common non-Hodgkin lymphoma (NHL) subtype. The histological transformation (HT) of FL is an event considered frequent in the natural history of this tumor. We studied the transformation rates, predictive factors and treatment characteristics that may impact in the survival of patients with FL and HT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2601DOI Listing

Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma.

Br J Haematol 2019 Feb 28. Epub 2019 Feb 28.

Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

In a prospective phase II trial, pentostatin combined with cyclophosphamide and rituximab (PCR) induced strong responses and was well-tolerated in previously untreated patients with advanced-stage, indolent non-Hodgkin lymphoma (iNHL). After a median patient follow-up of more than 108 months, we performed an intent-to-treat analysis of our 83 participants. Progression-free survival (PFS) rates at 108 months for follicular lymphoma (FL), marginal zone lymphoma (MZL) and small lymphocytic lymphoma (SLL) were 71%, 67% and 15%, respectively, and were affected by clinicopathological characteristics. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/bjh.15814
Publisher Site
http://dx.doi.org/10.1111/bjh.15814DOI Listing
February 2019
3 Reads

Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation: A Consensus Project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT.

JAMA Oncol 2019 Feb 28. Epub 2019 Feb 28.

Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee.

Importance: Maintenance therapies are often considered as a therapeutic strategy in patients with lymphoma following autologous hematopoietic cell transplantation (auto-HCT) to mitigate the risk of disease relapse. With an evolving therapeutic landscape, where novel drugs are moving earlier in therapy lines, evidence relevant to contemporary practice is increasingly limited. The American Society for Blood and Marrow Transplantation (ASBMT), Center for International Blood and Marrow Transplant Research (CIBMTR), and European Society for Blood and Marrow Transplantation (EBMT) jointly convened an expert panel with diverse expertise and geographical representation to formulate consensus recommendations regarding the use of maintenance and/or consolidation therapies after auto-HCT in patients with lymphoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2018.6278DOI Listing
February 2019
2 Reads

Copanlisib: An Intravenous Phosphatidylinositol 3-Kinase (PI3K) Inhibitor for the Treatment of Relapsed Follicular Lymphoma.

Ann Pharmacother 2019 Feb 27:1060028019833992. Epub 2019 Feb 27.

1 Sylvester Comprehensive Cancer Center, Hollywood, FL, USA.

Objective: To review the mechanism of action, clinical efficacy, safety, dosage, administration, and role of copanlisib in the treatment of relapsed follicular lymphoma (FL).

Data Sources: Sources of information were identified through searches of PubMed (August 2014 to January 2019) using the key terms copanlisib, Aliqopa, PI3K inhibitor, and BAY 80-6946. Unpublished abstract information was obtained from the American Society of Clinical Oncology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019833992DOI Listing
February 2019

Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies.

Blood 2019 Feb 25. Epub 2019 Feb 25.

University of Michigan, Ann Arbor, MI, United States.

This phase 1/2 study assessed parsaclisib (INCB050465), a next-generation, potent, and highly selective phosphatidylinositol 3-kinase δ (PI3Kδ) inhibitor, in patients with relapsed or refractory B-cell malignancies, alone or in combination with a Janus kinase 1 inhibitor (itacitinib) or chemotherapy (rituximab, ifosfamide, carboplatin, and etoposide). Seventy-two patients received parsaclisib monotherapy (5-45 mg once daily). Expansion doses were 20 and 30 mg once daily; intermittent dosing at 20 mg (once daily for 9 weeks, then once weekly) was explored. Read More

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/lookup/doi/10.1182/blood-2018-08
Publisher Site
http://dx.doi.org/10.1182/blood-2018-08-867499DOI Listing
February 2019
3 Reads

American Registry of Pathology Expert Opinions: Immunohistochemical evaluation of classic Hodgkin lymphoma.

Ann Diagn Pathol 2019 Feb 6;39:105-110. Epub 2019 Feb 6.

Mayo Clinic, Rochester, MN, United States of America.

The diagnosis of classic Hodgkin lymphoma requires immunohistochemical confirmation in most cases and one can argue for these studies as standard-of-care in the diagnostic workup. The authors propose a panel of studies for primary identification of CHL to include: CD3, CD20, CD15, CD30 and PAX5. When pattern discordances are identified, additional assessment is recommended. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.anndiagpath.2019.02.001DOI Listing
February 2019
1 Read

[The complex morphologic diagnostic of marginal zone lymphoma.]

Klin Lab Diagn 2017 ;62(8):490-497

The P.A. Hertsen Moscow research oncologic institute, the branch of the National medical radiologic research center of Minzdrav of Russia, 125284, Moscow, Russia.

The purpose of study: To determine possibilities of complex morphological diagnostic (routine cytology and histology, immunocytochemistry and immunohistochemistry, molecular genetics) of lymphoma of marginal zone. The study included 10 patients with diagnosis of lymphoma of marginal zone cells, established on the basis of application of morphological (cytological and histological), immunomorphologic (immunocytochemical and immunohistochemical) and molecular genetic techniques. The immunofenotyping was implemented using immunocytochemical technique (EnVision FLEX) applying monoclonal antibodies by DAKO manufacturer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18821/0869-2084-2017-62-8-490-497DOI Listing
January 2017

Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma.

PLoS One 2019 25;14(2):e0212813. Epub 2019 Feb 25.

Lymphoma Research Group, Medical Oncology Department, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain.

Follicular lymphoma (FL) is an indolent but largely incurable disease. Some patients suffer histological transformation to a more aggressive subtype with poorer prognosis. This study aimed to improve our understanding of the genetics underlying FL histological transformation, and to identify genetic drivers or promoters of the transformation by elucidating the differences between FL samples from patients who did and did not transform. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0212813PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388933PMC
February 2019
1 Read

Multimodality imaging of indolent B cell lymphoma from diagnosis to transformation: what every radiologist should know.

Insights Imaging 2019 Feb 22;10(1):25. Epub 2019 Feb 22.

Department of Imaging, Dana Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA, 02215, USA.

Indolent B cell lymphomas are a group of lymphoid malignancies characterized by their potential to undergo histologic transformation to aggressive lymphomas. While different subtypes of indolent B cell lymphomas demonstrate specific clinical and imaging features, histologic transformation can be suspected on cross-sectional imaging when disproportionate lymph node enlargement or new focal lesions in extranodal organs are seen. On PET/CT, transformed indolent lymphoma may show new or increased nodal FDG avidity or new FDG-avid lesions in different organs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13244-019-0705-yDOI Listing
February 2019
2 Reads

Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma.

Clin Lymphoma Myeloma Leuk 2019 Jan 2. Epub 2019 Jan 2.

Division of Cancer Medicine, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:

Background: Daratumumab is a CD38 monoclonal antibody approved for treating relapsed/refractory and newly diagnosed multiple myeloma. Preclinical daratumumab studies demonstrated cytotoxic activity and reduced tumor growth in B-cell non-Hodgkin lymphoma (NHL) subtypes, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle-cell lymphoma (MCL).

Patients And Methods: This was a phase 2, open-label, multicenter, 2-stage trial. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S21522650183128
Publisher Site
http://dx.doi.org/10.1016/j.clml.2018.12.013DOI Listing
January 2019
6 Reads

Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome.

Authors:

Hematol Oncol 2019 Feb;37(1):114

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2526DOI Listing
February 2019
1 Read

Outcome of transformed follicular lymphoma worsens according to the timing of transformation and to the number of previous therapies. A retrospective multicenter study on behalf of Fondazione Italiana Linfomi (FIL).

Br J Haematol 2019 Feb 21. Epub 2019 Feb 21.

Haematology, ASST Spedali Civili di Brescia, Brescia, Italy.

Optimal treatment for transformed follicular lymphoma (tFL) is not fully defined. Clinical characteristics and treatments that impact on post-transformation outcome of 176 biopsy-proven tFL were analysed. Transformation occurred at initial diagnosis in 52% (Group 1) and after a FL diagnosis in 48% (Group 2). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15816DOI Listing
February 2019

Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population.

Br J Haematol 2019 Feb 22. Epub 2019 Feb 22.

Haematology Department, Hospital Clínic de Barcelona, Barcelona, Spain.

The use of immunochemotherapy has improved the outcome of follicular lymphoma (FL). Recently, complete response at 30 months (CR30) has been suggested as a surrogate for progression-free survival. This study aimed to analyse the life expectancy of FL patients according to their status at 30 months from the start of treatment in comparison with the sex and age-matched Spanish general population (relative survival; RS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15805DOI Listing
February 2019
5 Reads

Distinctive incidence patterns of follicular lymphoma in Taiwan: Implications of ethnic differences.

Cancer Med 2019 Feb 21. Epub 2019 Feb 21.

Graduate Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan.

Background: Follicular lymphoma (FL) is less prevalent in Asians, but detailed epidemiological analyses were not available. This study aimed to characterize the epidemiologic features of FL in Taiwan to explore the factors relevant to disease development and prognosis.

Methods: We obtained epidemiological data for Taiwanese citizens during 1990-2012 from Taiwan's National Cancer Registry Database, and the corresponding data for US Caucasians from the Surveillance, Epidemiology, and End Results Program. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.2028DOI Listing
February 2019
1 Read

The Utility of Phosphohistone H3 (PHH3) in Follicular Lymphoma Grading.

Am J Clin Pathol 2019 Feb 21. Epub 2019 Feb 21.

Department of Pathology, Brooke Army Medical Center, San Antonio, TX.

Objectives: To determine the utility of phosphohistone H3 (PHH3) mitotic count (MC) in grading follicular lymphoma (FL).

Methods: FL cases were identified (2005-2017). Three hematopathologists recorded their average Ki-67 proliferation index, MC/high-power field (hpf) using PHH3 and H&E stains, and number of centroblasts/hpf. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/ajcp/advance-article/doi/10.1093/aj
Publisher Site
http://dx.doi.org/10.1093/ajcp/aqz003DOI Listing
February 2019
1 Read

Mass Cytometry Analysis Reveals that Specific Intratumoral CD4 T Cell Subsets Correlate with Patient Survival in Follicular Lymphoma.

Cell Rep 2019 Feb;26(8):2178-2193.e3

Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA. Electronic address:

Follicular lymphoma (FL) is an indolent B cell malignancy characterized by an extensive but poorly functional T cell infiltrate in the tumor microenvironment. Using mass cytometry, we identified at least 12 subsets of intratumoral CD4 T cells, 3 of which were unique to FL biopsies versus control tissues. Of these subsets, the frequency of naive T cells correlated with improved patient survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2019.01.085DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6402596PMC
February 2019
2 Reads

Short survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentation.

Am J Hematol 2019 Feb 19. Epub 2019 Feb 19.

Division of Hematology, Department of Medicine, University of Miami, Miller School of Medicine, Miami, Florida.

Between 11 and 37% of extranodal marginal zone lymphoma (EMZL) patients present with disease involvement in multiple mucosal sites (MMS). We analyzed 405 EMZL patients seen between 1995 and 2017: 265 (65.4%) patients presented with stage I disease, 49 of 309 (15. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25446DOI Listing
February 2019
1 Read

New directions in treating peripheral T-cell lymphomas (PTCL): leveraging epigenetic modifiers alone and in combination.

Expert Rev Hematol 2019 Feb 20:1-10. Epub 2019 Feb 20.

a Center for Lymphoid Malignancies, Division of Hematology and Oncology, Department of Medicine , Columbia University Medical Center, College of Physicians and Surgeons , New York , NY , USA.

Introduction: The peripheral T-cell lymphomas (PTCL) are a rare and heterogeneous group of non-Hodgkin lymphomas originating from mature T- and NK-cells. They are aggressive diseases often resistant to chemotherapy. Areas Covered: The methodology of this review involves a literature search of data published on PubMed, abstracts from international conferences, and our own research. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1583102DOI Listing
February 2019
4 Reads

Baseline PET as prognostic index in diffuse large B-cell lymphoma and grade IIIb follicular lymphoma: a retrospective study of a single-centre experience.

Q J Nucl Med Mol Imaging 2019 Feb 14. Epub 2019 Feb 14.

Department of Medicine and Surgery, University of Insubria, Varese, Italy.

Background: International guidelines support performing baseline positron emission tomography (PET) in lymphoma. Metabolic tumor volume (MTV) measurement has been proposed as a good measurement of disease burden. We investigated if MTV at baseline PET can be predictive of complete response (CR) to first line standard chemotherapy in diffuse large B-cell lymphoma (DLBCL) and in follicular lymphoma (FL) grade 3b. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.23736/S1824-4785.19.03130-3DOI Listing
February 2019
2 Reads

MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR.

Methods Mol Biol 2019 ;1956:199-228

Second Medical Department, University Hospital Schleswig-Holstein, Kiel, Germany.

Minimal residual disease (MRD) diagnostics is of high clinical relevance in patients with indolent B-cell non-Hodgkin lymphomas (B-NHL) and serves as a surrogate parameter to evaluate treatment effectiveness and long-term prognosis. MRD diagnostics performed by real-time quantitative PCR (RQ-PCR) is still the gold standard and currently the most sensitive and the most broadly applied method in follicular lymphoma (FL) and mantle cell lymphoma (MCL). Alternatively, droplet digital PCR (ddPCR) can be used for MRD monitoring in multiple myeloma, mantle cell lymphoma, and follicular lymphoma with comparable sensitivity, accuracy, and reproducibility. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4939-9151-8_9DOI Listing
January 2019
2 Reads

Thoracoscopic Diagnosis of Follicular Lymphoma Relapsing after 13 Years.

Surg J (N Y) 2019 Jan 14;5(1):e5-e7. Epub 2019 Feb 14.

Department of Thoracic Surgery, Sureyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, Turkey.

Relapse in lymphoproliferative malignancies is not an exceptional entity and generally occurs within the first 2 or 3 years following the primary treatment. Lymph node biopsy is essential for the diagnosis of relapse and treatment. A 64-years-old woman was referred to our clinic for back pain and dyspnea. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0038-1661416DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6375731PMC
January 2019
1 Read

[Clinicopathological features and possible prognostic factors in parotid lymphomas].

Beijing Da Xue Xue Bao Yi Xue Ban 2019 Feb;51(1):35-42

Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Laboratory for Digital and Material Technology of Stomatology & Beijing Key Laboratory of Digital Stomatology, Beijing 100081, China.

Objective: To investigate the clinicopathological features and prognostic factors in lymphoma of parotid origin.

Methods: Clinicopathological data of the patients with parotid lymphoma who were initially diagnosed in Peking University Hospital of Stomatology from 2006 to 2016 were collected and analyzed retrospectively. The patients were followed-up for 5 to 149 months with a median period of 45 months, and the factors influencing the prognosis were evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19723/j.issn.1671-167X.2019.01.007DOI Listing
February 2019
1 Read

Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma.

Br J Haematol 2019 Feb 14. Epub 2019 Feb 14.

Celgene Corporation, Summit, NJ, USA.

Chemotherapy plus rituximab has been the mainstay of treatment for follicular lymphoma (FL) for two decades but is associated with immunosuppression and relapse. In phase 2 studies, lenalidomide combined with rituximab (R ) has shown clinical synergy in front-line and relapsed/refractory FL. Here, we show that lenalidomide reactivated dysfunctional T and Natural Killer (NK) cells ex vivo from FL patients by enhancing proliferative capacity and T-helper cell type 1 (Th1) cytokine release. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15797DOI Listing
February 2019
5 Reads

DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma.

J Clin Oncol 2019 Feb 11:JCO1800915. Epub 2019 Feb 11.

19 University of Bologna, Bologna, Italy.

Purpose: Indolent non-Hodgkin lymphoma (iNHL) remains largely incurable and often requires multiple lines of treatment after becoming refractory to standard therapies. Duvelisib was approved by the Food and Drug Administration for relapsed or refractory (RR) chronic lymphocytic leukemia or small lymphocytic lymphoma (SLL) and RR follicular lymphoma (FL) after two or more prior systemic therapies. On the basis of the activity of duvelisib, a first-in-class oral dual inhibitor of phosphoinositide 3-kinase-δ,-γ, in RR iNHL in a phase I study, the safety and efficacy of duvelisib monotherapy was evaluated in iNHL refractory to rituximab and either chemotherapy or radioimmunotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.18.00915DOI Listing
February 2019
1 Read

Residential ambient benzene exposure in the United States and subsequent risk of hematologic malignancies.

Int J Cancer 2019 Feb 9. Epub 2019 Feb 9.

Epidemiology Research Group, American Cancer Society, Atlanta, GA.

Benzene is considered a carcinogen, mostly based on evidence of causality for myeloid leukemia from high levels of exposure in occupational studies. We used United States Environmental Protection Agency National Ambient Toxics Assessment (NATA) estimates of low-level ambient benzene to examine potential associations for the general public between benzene exposure and risk of hematologic cancers. Exposure was estimated by linking participants' residential address to the NATA benzene estimates for that census tract. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.32202DOI Listing
February 2019
1 Read

Differential expression of estrogen receptor-α on follicular dendritic cells from patients with grade 1-2 and grade 3 follicular lymphoma.

Hematol Oncol 2019 Feb 8. Epub 2019 Feb 8.

Department of Pathological Diagnostics, Yamagata University Faculty of Medicine, Yamagata, Japan.

Hormone therapy has been used for patients with estrogen receptor alpha (ERα)-positive breast cancers. Recently, some studies reported the expression of ERα on neoplastic cells from B cell lymphomas. However, there has been only one report of ERα expression on the follicular dendritic cells (FDCs) that structurally and functionally support the microenvironment of follicular lymphomas (FLs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2577DOI Listing
February 2019
1 Read

Is Longer Progression-Free Survival a Goal Worth Pursuing in Follicular Lymphoma?

J Clin Oncol 2019 Mar 8;37(9):758. Epub 2019 Feb 8.

Marc Sorigue, MD and Juan-Manuel Sancho, MD, PhD, Institut Catala d'Oncologia, Badalona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.18.01761DOI Listing

A patient with a diagnosis of nodal marginal zone B-cell lymphoma and a t(2;14)(p24;q32) involving and .

Mol Cytogenet 2019 1;12. Epub 2019 Feb 1.

Department of Pathology, Nelson Hospital, 115 Kawai St, Nelson South, Nelson, 7010 New Zealand.

Background: Nodal marginal zone B-cell lymphoma is a rare entity in which the cytogenetic findings are not well defined. The t(2;14)(p24;q32) has previously been reported in three patients with blastic mantle cell lymphoma and one patient with follicular lymphoma. This rearrangement has not been reported previously in a patient with a diagnosis of nodal marginal zone B-cell lymphoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13039-019-0419-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6359751PMC
February 2019
1 Read

[Follicular lymphoma accompanied by paraneoplastic pemphigus and bronchiolitis obliterans: a case report].

Rinsho Ketsueki 2019 ;60(1):7-11

Department of Hematology, Tokyo Medical and Dental University.

A 54-year-old female complained of oral erosion. A flaccid blister appeared on the trunk 2 months after the onset. The high titer of the anti-desmoglein 1 antibody in the absence of Nikolsky's sign led to the diagnosis of pemphigus vulgaris. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11406/rinketsu.60.7DOI Listing
January 2019
2 Reads

Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance).

Br J Haematol 2019 Feb 5. Epub 2019 Feb 5.

Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, DC, USA.

Rituximab monotherapy has proven efficacy in treatment-naïve, asymptomatic advanced-stage follicular lymphoma (FL). Ofatumumab is a fully humanized anti-CD20 monoclonal antibody with increased CD20 affinity and complement-dependent cytotoxicity. This phase 2 trial (NCT01190449) evaluated ofatumumab in patients with untreated, low/intermediate-risk FL International Prognostic Index (FLIPI), advanced-stage FL to determine single-agent efficacy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15768DOI Listing
February 2019
2 Reads